Therapeutic schemes in 177Lu and 90Y-PRRT: radiobiological considerations

A. Sarnelli, F. Guerriero, F. Botta, M. Ferrari, L. Strigari, L. Bodei, V. D'Errico, E. Grassi, F. Fioroni, G. Paganelli, R. Orecchia, M. Cremonesi

Research output: Contribution to journalArticle

Abstract

BACKGROUND: The purpose of this work is to implement a radiobiological model to compare different treatment schedules for Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu and 90Y. The principal radiobiological quantities were studied as a function of radionuclides, fractionation schemes, activity distribution in kidneys and tumor radiosensitivity. METHODS: Clinical data were used to derive representative absorbed doses for several treatment schemes for 177Lu-PRRT and for 90Y-PRRT and considered as input data for the radiobiological model. Both uniform and non-uniform activity distributions were considered for kidneys and cortex; for tumors a possible uptake reduction after each cycle and inter-patient radiosensitivity variability were investigated. Normal-Tissue-Complication-Probability (NTCP) and Tumor-Control-Probability (TCP) were evaluated. RESULTS: Hyper-cycling has a limited advantage in terms of BED reduction on kidneys for 177Lu, while for 90Y the effect is sizable and helps in reducing the NTCP. For all 177Lu-schemes the renal toxicity risk is negligible while for some 90Y-schemes the NTCP is not null. In case of tumor uptake reduction with cycles the treatment efficacy is reduced with a BED loss up to 46%. The TCP decreases when assuming normally-distributed tumor radiosensitivity values. CONCLUSIONS: This paper discusses how the combination of dosimetry and radiobiological modeling may help in exploring the link between the treatment schedule and the potential clinical outcome. The results highlight the capability of model to reproduce the available clinical data and provide useful qualitative information. Further investigation on dose distribution and dose uptake reduction with accurate clinical data is needed to progress in this field.
Original languageEnglish
Pages (from-to)216-231
Number of pages16
JournalQuarterly Journal of Nuclear Medicine and Molecular Imaging
Volume61
Issue number2
Publication statusPublished - 2017

Cite this

Sarnelli, A., Guerriero, F., Botta, F., Ferrari, M., Strigari, L., Bodei, L., ... Cremonesi, M. (2017). Therapeutic schemes in 177Lu and 90Y-PRRT: radiobiological considerations. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 61(2), 216-231.

Therapeutic schemes in 177Lu and 90Y-PRRT: radiobiological considerations. / Sarnelli, A.; Guerriero, F.; Botta, F.; Ferrari, M.; Strigari, L.; Bodei, L.; D'Errico, V.; Grassi, E.; Fioroni, F.; Paganelli, G.; Orecchia, R.; Cremonesi, M.

In: Quarterly Journal of Nuclear Medicine and Molecular Imaging, Vol. 61, No. 2, 2017, p. 216-231.

Research output: Contribution to journalArticle

Sarnelli, A, Guerriero, F, Botta, F, Ferrari, M, Strigari, L, Bodei, L, D'Errico, V, Grassi, E, Fioroni, F, Paganelli, G, Orecchia, R & Cremonesi, M 2017, 'Therapeutic schemes in 177Lu and 90Y-PRRT: radiobiological considerations', Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 61, no. 2, pp. 216-231.
Sarnelli, A. ; Guerriero, F. ; Botta, F. ; Ferrari, M. ; Strigari, L. ; Bodei, L. ; D'Errico, V. ; Grassi, E. ; Fioroni, F. ; Paganelli, G. ; Orecchia, R. ; Cremonesi, M. / Therapeutic schemes in 177Lu and 90Y-PRRT: radiobiological considerations. In: Quarterly Journal of Nuclear Medicine and Molecular Imaging. 2017 ; Vol. 61, No. 2. pp. 216-231.
@article{9d5b61d170784c3ebae99afc60190d7e,
title = "Therapeutic schemes in 177Lu and 90Y-PRRT: radiobiological considerations",
abstract = "BACKGROUND: The purpose of this work is to implement a radiobiological model to compare different treatment schedules for Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu and 90Y. The principal radiobiological quantities were studied as a function of radionuclides, fractionation schemes, activity distribution in kidneys and tumor radiosensitivity. METHODS: Clinical data were used to derive representative absorbed doses for several treatment schemes for 177Lu-PRRT and for 90Y-PRRT and considered as input data for the radiobiological model. Both uniform and non-uniform activity distributions were considered for kidneys and cortex; for tumors a possible uptake reduction after each cycle and inter-patient radiosensitivity variability were investigated. Normal-Tissue-Complication-Probability (NTCP) and Tumor-Control-Probability (TCP) were evaluated. RESULTS: Hyper-cycling has a limited advantage in terms of BED reduction on kidneys for 177Lu, while for 90Y the effect is sizable and helps in reducing the NTCP. For all 177Lu-schemes the renal toxicity risk is negligible while for some 90Y-schemes the NTCP is not null. In case of tumor uptake reduction with cycles the treatment efficacy is reduced with a BED loss up to 46{\%}. The TCP decreases when assuming normally-distributed tumor radiosensitivity values. CONCLUSIONS: This paper discusses how the combination of dosimetry and radiobiological modeling may help in exploring the link between the treatment schedule and the potential clinical outcome. The results highlight the capability of model to reproduce the available clinical data and provide useful qualitative information. Further investigation on dose distribution and dose uptake reduction with accurate clinical data is needed to progress in this field.",
keywords = "Adult, Algorithms, Female, Humans, Kidney/radiation effects, Lutetium/therapeutic use, Male, Middle Aged, Models, Biological, Neuroendocrine Tumors/metabolism/radiotherapy, Organs at Risk, Radioisotopes/therapeutic use, Radiometry, Radiotherapy/methods, Receptors, Peptide/metabolism, Yttrium Radioisotopes/therapeutic use",
author = "A. Sarnelli and F. Guerriero and F. Botta and M. Ferrari and L. Strigari and L. Bodei and V. D'Errico and E. Grassi and F. Fioroni and G. Paganelli and R. Orecchia and M. Cremonesi",
note = "LR: 20170411; JID: 101213861; 0 (Radioisotopes); 0 (Receptors, Peptide); 0 (Yttrium Radioisotopes); 5H0DOZ21UJ (Lutetium); ppublish M1 - Journal Article",
year = "2017",
language = "English",
volume = "61",
pages = "216--231",
journal = "Quarterly Journal of Nuclear Medicine and Molecular Imaging",
issn = "1824-4785",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "2",

}

TY - JOUR

T1 - Therapeutic schemes in 177Lu and 90Y-PRRT: radiobiological considerations

AU - Sarnelli, A.

AU - Guerriero, F.

AU - Botta, F.

AU - Ferrari, M.

AU - Strigari, L.

AU - Bodei, L.

AU - D'Errico, V.

AU - Grassi, E.

AU - Fioroni, F.

AU - Paganelli, G.

AU - Orecchia, R.

AU - Cremonesi, M.

N1 - LR: 20170411; JID: 101213861; 0 (Radioisotopes); 0 (Receptors, Peptide); 0 (Yttrium Radioisotopes); 5H0DOZ21UJ (Lutetium); ppublish M1 - Journal Article

PY - 2017

Y1 - 2017

N2 - BACKGROUND: The purpose of this work is to implement a radiobiological model to compare different treatment schedules for Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu and 90Y. The principal radiobiological quantities were studied as a function of radionuclides, fractionation schemes, activity distribution in kidneys and tumor radiosensitivity. METHODS: Clinical data were used to derive representative absorbed doses for several treatment schemes for 177Lu-PRRT and for 90Y-PRRT and considered as input data for the radiobiological model. Both uniform and non-uniform activity distributions were considered for kidneys and cortex; for tumors a possible uptake reduction after each cycle and inter-patient radiosensitivity variability were investigated. Normal-Tissue-Complication-Probability (NTCP) and Tumor-Control-Probability (TCP) were evaluated. RESULTS: Hyper-cycling has a limited advantage in terms of BED reduction on kidneys for 177Lu, while for 90Y the effect is sizable and helps in reducing the NTCP. For all 177Lu-schemes the renal toxicity risk is negligible while for some 90Y-schemes the NTCP is not null. In case of tumor uptake reduction with cycles the treatment efficacy is reduced with a BED loss up to 46%. The TCP decreases when assuming normally-distributed tumor radiosensitivity values. CONCLUSIONS: This paper discusses how the combination of dosimetry and radiobiological modeling may help in exploring the link between the treatment schedule and the potential clinical outcome. The results highlight the capability of model to reproduce the available clinical data and provide useful qualitative information. Further investigation on dose distribution and dose uptake reduction with accurate clinical data is needed to progress in this field.

AB - BACKGROUND: The purpose of this work is to implement a radiobiological model to compare different treatment schedules for Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu and 90Y. The principal radiobiological quantities were studied as a function of radionuclides, fractionation schemes, activity distribution in kidneys and tumor radiosensitivity. METHODS: Clinical data were used to derive representative absorbed doses for several treatment schemes for 177Lu-PRRT and for 90Y-PRRT and considered as input data for the radiobiological model. Both uniform and non-uniform activity distributions were considered for kidneys and cortex; for tumors a possible uptake reduction after each cycle and inter-patient radiosensitivity variability were investigated. Normal-Tissue-Complication-Probability (NTCP) and Tumor-Control-Probability (TCP) were evaluated. RESULTS: Hyper-cycling has a limited advantage in terms of BED reduction on kidneys for 177Lu, while for 90Y the effect is sizable and helps in reducing the NTCP. For all 177Lu-schemes the renal toxicity risk is negligible while for some 90Y-schemes the NTCP is not null. In case of tumor uptake reduction with cycles the treatment efficacy is reduced with a BED loss up to 46%. The TCP decreases when assuming normally-distributed tumor radiosensitivity values. CONCLUSIONS: This paper discusses how the combination of dosimetry and radiobiological modeling may help in exploring the link between the treatment schedule and the potential clinical outcome. The results highlight the capability of model to reproduce the available clinical data and provide useful qualitative information. Further investigation on dose distribution and dose uptake reduction with accurate clinical data is needed to progress in this field.

KW - Adult

KW - Algorithms

KW - Female

KW - Humans

KW - Kidney/radiation effects

KW - Lutetium/therapeutic use

KW - Male

KW - Middle Aged

KW - Models, Biological

KW - Neuroendocrine Tumors/metabolism/radiotherapy

KW - Organs at Risk

KW - Radioisotopes/therapeutic use

KW - Radiometry

KW - Radiotherapy/methods

KW - Receptors, Peptide/metabolism

KW - Yttrium Radioisotopes/therapeutic use

M3 - Article

VL - 61

SP - 216

EP - 231

JO - Quarterly Journal of Nuclear Medicine and Molecular Imaging

JF - Quarterly Journal of Nuclear Medicine and Molecular Imaging

SN - 1824-4785

IS - 2

ER -